When was Affini-T Therapeutics founded?

Affini-T Therapeutics was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Affini-T Therapeutics located?

Affini-T Therapeutics is headquartered in Watertown, United States.

Who is the current CEO of Affini-T Therapeutics?

Jak Knowles of Affini-T Therapeutics. They have also founded 1 company.

How many employees does Affini-T Therapeutics have?

As of Mar 31, 2026, the latest employee count at Affini-T Therapeutics is 12.

Is Affini-T Therapeutics a funded company?

Affini-T Therapeutics is a funded company, having raised a total of $193M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2020.

When was the latest funding round of Affini-T Therapeutics?

Affini-T Therapeutics' latest funding was a $***** Series D round on Jul 31, 2024, with participation from 0 investor.

Where does Affini-T Therapeutics rank among its competitors?

Affini-T Therapeutics ranks 700th amongst 3278 active competitors, of which 1127 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Affini-T Therapeutics?

Affini-T Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Moderna secured the most recent funding round in January, 2025.

Affini-T Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of T-cell therapies against oncogenic driver mutations. The company has a TCR discovery platform that leverages synthetic biology and gene editing technologies to develop therapies for solid tumor cancers. The company has developed therapies targeting oncogenic driver mutations like KRAS and p53.

Website: affinittx.com
Social
Email ID: *****@affinittx.com

Key Metrics

Founded Year

2020

Location

Watertown, United States

Stage

Series D

Total Funding

$193M in 5 rounds

Latest Funding Round

Series D, Jul 31, 2024, $*****

Investors

Bayer & 9 more

Ranked

700^th among 3278 active competitors

Employee Count

12 as on Mar 31, 2026

Similar Companies

BeiGene & 782 more

View Affini-T Therapeutics' full profile

Affini-T Therapeutics has raised a total funding of $193M over 5 rounds. Its first funding round was on Apr 01, 2020. Affini-T Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Affini-T Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 31, 2024	4010967	Series D	6683429	9208091	7219673	8733147
Mar 22, 2022	5578908	Series D	4794223	7454326	8417311	Fred Hutch & 6 more
Jul 01, 2020	1944534	Grant (prize money)	1351006	3140344	9845278	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Affini-T Therapeutics's funding rounds and investors

The founders of Affini-T Therapeutics is Jak Knowles. Jak Knowles is the CEO of Affini-T Therapeutics.

Here are the details of Affini-T Therapeutics' key team members:

Jak Knowles: Co-founder, President & CEO of Affini-T Therapeutics.

View details of Affini-T Therapeutics's Founder profiles and Board Members

Affini-T Therapeutics' employee count trend

Affini-T Therapeutics has 12 employees as of Mar 26. Here is Affini-T Therapeutics's employee count trend over the years:

Employee count trend for Affini-T Therapeutics

Uncover Affini-T Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Affini-T Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Affini-T Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Kaccelerator, BB Biotech & 7 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
700th	Affini-T Therapeutics 2020, Watertown (United States), Series D	Developer of T-cell therapies against oncogenic driver mutations	$193M	Alexandria, Agent Capital & 8 others	49/100